New study tests tofacitinib for kids with arthritis
NCT ID NCT07211932
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test the drug tofacitinib in 58 children with juvenile idiopathic arthritis (JIA) to see if it improves disease control after 12 months. Researchers will use real-world medical records to measure changes in arthritis activity. The goal is to find out if tofacitinib is a helpful treatment option for kids with JIA.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib
What this could lead to
If it works, this could show that tofacitinib is an effective option for controlling juvenile idiopathic arthritis in children.
What could go wrong
This is a small, early-stage real-world study with only 58 participants, so results may not apply broadly. Tofacitinib can have side effects like increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Sant Joan de Déu Barcelona
Barcelona, Barcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital de Vilafranca
Vilafranca del Penedès, Barceona, 08720, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact